Novo Nordisk Launches Wegovy Pill in US, Challenging Eli Lilly
Novo Nordisk has introduced its once-daily Wegovy pill in the US, offering a needle-free alternative in the weight-loss drug market. The pill, priced between $149 and $299 per month, aims to compete with Eli Lilly's injectable offerings.
Insights:
Novo Nordisk A/S has officially launched its once-daily Wegovy pill in the United States, marking a significant shift in the competitive landscape of the weight-loss drug market. Approved by the U.S. Food and Drug Administration (FDA) in December 2024, the pill became available on January 6, 2025. It is priced between $149 and $299 per month, depending on the dosage, and is designed to attract cash-paying consumers seeking a needle-free alternative to injectable treatments.
